Scil Technology develops biopharmaceutical drugs by combining proteins with special formulation technologies for the treatment of various diseases

As part of its business unit Biologics Development, Scil Technology GmbH develops not only successfully innovative biopharmaceutical drug candidates based on proprietary proteins, but also has the expertise to design tailor-made formulations for well known proteins to extend their field of application. Thus Scil Technology made it their business to create innovative disease modifying biopharmaceuticals from early research up to phase III.